论文部分内容阅读
目的:观察奥沙利铂联合替吉奥治疗晚期胃癌的近期疗效和不良反应。方法:58例晚期胃癌患者,予奥沙利铂和替吉奥化疗,21天为1个周期,按RECIST1.0标准评价客观疗效和不良反应。结果:CR4例,PR28例,SD15例,PD9例,有效率55.2%。中位疾病进展时间6个月,中位生存期10个月。主要的不良反应为骨髓抑制、消化道毒性及外周神经毒性,均为可逆性。结论:奥沙利铂联合替吉奥方案治疗晚期胃癌的近期疗较好,不良反应发生率低,安全性较好,更适合年老体弱患者。
Objective: To observe the short-term efficacy and side effects of oxaliplatin combined with tirofiban in the treatment of advanced gastric cancer. Methods: Fifty-eight patients with advanced gastric cancer were treated with oxaliplatin and tioguanide for 21 days. The objective and adverse effects were evaluated according to RECIST1.0 standard. Results: CR4 cases, PR28 cases, SD15 cases, PD9 cases, the effective rate was 55.2%. The median time to disease progression is 6 months, with a median survival of 10 months. The main adverse reactions were myelosuppression, gastrointestinal toxicity and peripheral neurotoxicity, all of which were reversible. Conclusion: The combination of oxaliplatin and tiagogol for the treatment of advanced gastric cancer is better, the incidence of adverse reactions is lower, the safety is better, and it is more suitable for the elderly and infirm patients.